Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: TRI

Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccine

VANCOUVER, BC, Feb. 2, 2023 /CNW Telbec/ - Platform Life Sciences, a high impact Clinical Research Organization, with the mission to modernize clinical trials on a global scale, has signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda ? that today has been approved by the Rwanda FDA.

The trial will be performed by leading clinical investigators in Rwanda, in partnership with Platform Life Sciences. Rwandan scientific leaders have conducted several clinical trials for large pharmaceutical companies and are at the forefront of advancing end-to-end research and development in Africa.

Platform Life Sciences has built an innovative global partnerships network for executing clinical trials with modern technology and infrastructure that has the potential to lower costs and accelerate the time to market for products.  The network has expertise in COVID-19, vaccines, viral respiratory, and other infectious diseases.

"We share a common vision with Platform Life Sciences of working towards global vaccine self-sufficiency and look forward to using Platform Life Sciences in the conduct of our clinical trial," said Andrey Zarur, CEO, and co-founder of GreenLight Biosciences.

In the last few years, global public health has been compromised by infectious diseases and outdated clinical trial practices. Platform Life Sciences has invested in the successful development of a complex global network of community-based sites, designing a configuration and workflows with infrastructure that can assess a protocol and mobilize Phase I, II, and III trials with great efficiency. Platform Life Sciences goes where the disease is and focuses on patient populations wherever they are located. Africa has been one of the highest economic growth regions in the world and has substantial potential for clinical research, production, and consumption ? including in Rwanda.

Platform Life Sciences has also created a Community of Practice across its investigators and sites to ensure constant quality improvement and innovation in how to conduct trials and to maximize investigator engagement to conduct trials more rapidly and, potentially, accelerate access to life-saving products.

"We are delighted with the approval of this trial by the Rwanda FDA. Trust, long-term relationships, and local expertise have all come together to allow us to move from protocol assessment to trial approval at due speed," said Dr. Ed Mills, founder, and Chief Science Officer of Platform Life Sciences. "We look forward to this Phase I with GreenLight Biosciences while we are already working on large scale trials that have the potential to rapidly recruit and complete clinical trials in many thousands of participants. 

About Platform Life Sciences.
For more information about Platform Life Sciences, please contact Platform Life Sciences at [email protected] or visit our website at www.platformlifesciences.com.

SOURCE Platform Life Sciences

These press releases may also interest you

at 01:00
CodeSteri, a leading provider of disinfection solutions, is proud to announce the launch of PlaClin-M, a revolutionary device designed to help ensure a clean and safe environment in offices, commercial establishments, and public spaces. CodeSteri...

at 00:01
As infectious disease outbreaks and extreme weather events threaten the health of more Americans, a new report shows the need for strengthened national and state public health emergency preparedness....

22 mar 2023
DURACORE, a manufacturer of high-performance active living products, has entered into an exclusive partnership with Five at Heart, a leading provider of bike room, change room, and modern office solutions based in Brisbane, Australia. The partnership...

22 mar 2023
Ionis today announced the outcome of the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational antisense medicine for the treatment of people with...

22 mar 2023
The "Research Antibodies and Reagents Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the...

22 mar 2023
The "Healthcare E-Commerce Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The...

News published on 2 february 2023 at 09:09 and distributed by: